320
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Inhibition of Motile and Invasive Properties of Ovarian Cancer Cells by ASODN Against Rho-associated Protein Kinase

, , , , , , , & show all
Pages 59-69 | Received 24 Jun 2005, Accepted 19 Sep 2005, Published online: 11 Jul 2009
 

Abstract

p160ROCK, a kinase effector of Rho GTPase mediating RhoA-induced assembly of focal adhesions and stress fibers, plays an important role in the invasive process of various tumor cells. The purpose of this study was to investigate the role of p160ROCK in the invasive behaviors of human ovarian cancer cells and their metastasis. Transfection with a dominant-active form of p160ROCK mutant (p160ROCKΔ 3) enhanced cell migration and invasion of ovarian cancer cells, while antisense oligodeoxynucleotide (ASODN) against p160ROCK inhibited the motile and invasive properties of the cells. Our data suggested that p160ROCK was involved in ovarian cancer cell invasion and metastasis by facilitating cancer cell migration, and that p160ROCK might be a potential new effective target for preventing metastasis of ovarian cancer.

Abbreviation
ROCK=

Rho-associated coiled-coil forming kinase

ASODN=

antisense oligodeoxynucleotide

SODN=

sense oligodeoxynucleotide

PBS=

phosphate-buffered saline

BSA=

bovine serum albumin

LIMK=

LIM kinase

MLC=

myosin light chain

ERM=

ezrin-radixin-moesin.

Abbreviation
ROCK=

Rho-associated coiled-coil forming kinase

ASODN=

antisense oligodeoxynucleotide

SODN=

sense oligodeoxynucleotide

PBS=

phosphate-buffered saline

BSA=

bovine serum albumin

LIMK=

LIM kinase

MLC=

myosin light chain

ERM=

ezrin-radixin-moesin.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.